SIGA Technologies to Host Business Update Call After Q3 Results
NEW YORK, Oct. 31, 2024 — SIGA Technologies, Inc. (NASDAQ: SIGA), a prominent pharmaceutical company, is set to conduct a webcast and conference call to discuss its business strategies and third-quarter financial results. The event will occur on Thursday, November 7, at 4:30 P.M. ET, featuring insights from CEO Diem Nguyen and CFO Daniel Luckshire.
Details of the Call and Participation
Investors and interested parties can tune into the call via a live webcast, accessible through the Company’s website in the Investor Relations section. Participants are encouraged to log in about 5-10 minutes prior to the event to ensure a smooth connection.
For those who prefer traditional phone access, the call can be joined by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international participants. This approach allows a wider audience to receive important updates directly from SIGA’s executive team.
Availability of Call Replay and Archiving
For anyone unable to attend the live session, a replay will be accessible for two weeks post-event. Domestic callers can replay by dialing 1-844-512-2921, while international callers can reach it at 1-412-317-6671—don’t forget to use Conference ID: 1146096. Additionally, the archived webcast will also be available on the Company’s website, ensuring that all interested stakeholders can stay informed of the latest end results and future prospects.
About SIGA Technologies
Founded with a mission to address critical health challenges, SIGA Technologies is focused on developing groundbreaking treatments for infectious diseases. Their flagship product, TPOXX® (tecovirimat), is notably recognized for its effectiveness against smallpox and is authorized for use in treating additional orthopoxvirus infections such as mpox (monkeypox). As a leader in global health, SIGA collaborates with various governments and health organizations to offer essential resources aimed at combating severe viral threats.
In a world where new health threats emerge regularly, SIGA stands at the forefront of innovation, ensuring that profound health solutions reach those in need. Their commitment aims to protect public health by providing effective antiviral treatments not just for smallpox, but also for closely related viral infections. As they aim to expand their product range, SIGA remains dedicated to improving health outcomes across the globe.
Contact Information
For further inquiries, SIGA encourages reaching out through the contact details provided below. Their team is ready to assist investors, media representatives, and any interested parties with information and clarity about their operations and initiatives.
Investor Relations Contacts
Suzanne Harnett
Email: sharnett@siga.com
Jennifer Drew-Bear, Edison Group
Email: Jdrew-bear@edisongroup.com
Media Relations Contacts
Holly Stevens, Berry & Company
Email: hstevens@berrypr.com
Frequently Asked Questions
What is the purpose of the upcoming business update call?
The call aims to provide insights into SIGA's financial results for Q3 2024 and an overall business update from the company's executives.
Who will be speaking during the call?
CEO Diem Nguyen and CFO Daniel Luckshire will be leading the discussion, sharing insights about the company's performance and future outlook.
How can I access the live webcast?
The live webcast can be accessed through SIGA's official website in the Investor Relations section, with a recommendation to log in 5-10 minutes early.
Is there an option to replay the call?
Yes, a call replay will be available for two weeks. Domestic participants can call 1-844-512-2921 and international callers can use 1-412-317-6671 to access it using the designated Conference ID.
What is TPOXX® and how does it relate to SIGA?
TPOXX® (tecovirimat) is SIGA's leading antiviral treatment approved for smallpox and related viruses, highlighting the company's commitment to combating significant infectious diseases globally.
